This would support the idea that the environmental pressure applied by HER2 inhibitors eventually results in the selection of treatment resistant clones, which are less addicted to the HER2 pathway, a known hallmark feature of cancer [165,166]. The gene discussed is ERBB2; the disease is cancer.